OTCMKTS:IPCIF Intellipharmaceutics International (IPCIF) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisChartSEC Filings About Intellipharmaceutics International Stock (OTCMKTS:IPCIF) Get IPCIF alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolumeN/AAverage Volume12,042 shsMarket Capitalization$4.96 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Intellipharmaceutics International Inc. was a Canadian specialty pharmaceutical company focused on developing and commercializing oral, controlled-release drug products. Its work centered on proprietary drug-delivery technologies designed to regulate the release of active pharmaceutical ingredients and support the development of extended-release and abuse-deterrent formulations. The company pursued both generic and novel prescription medicines, including extended-release versions of established drugs and its Rexista oxycodone product, an abuse-deterrent formulation developed for the treatment of pain. Intellipharmaceutics also sought regulatory approvals and commercial partnerships in the United States and Canada for selected products and product candidates. Founded in 1998 and based in Toronto, Ontario, Intellipharmaceutics was historically led by co-founder Dr. Isa Odidi. The company’s business activities were primarily directed toward pharmaceutical research, formulation development, regulatory submissions and licensing or partnering opportunities rather than operating a broad consumer-facing healthcare business.AI Generated. May Contain Errors. Read More Receive IPCIF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intellipharmaceutics International and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IPCIF Stock News HeadlinesIntellipharmaceutics International Inc. Announces Stock Option GrantFebruary 8, 2024 | finance.yahoo.comIntellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture ExchangeJanuary 2, 2024 | finance.yahoo.comDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratings' latest research says 2026 could be very rough for some well-known stocks. A major shift now taking shape in the market could hit some of America's most-loved names hard. Weiss analysts have pinpointed five stocks they believe investors should steer clear of while it plays out.November 14 at 1:00 AM | Weiss Ratings (Ad)Intellipharmaceutics International Inc.: Intellipharmaceutics Announces Third Quarter 2023 ResultsOctober 16, 2023 | finanznachrichten.deIntellipharmaceutics Announces Second Quarter 2023 ResultsJuly 14, 2023 | finance.yahoo.comClosing Bell: Intellipharmaceutics International Inc up on Monday (IPCI)June 27, 2023 | theglobeandmail.comClosing Bell: Intellipharmaceutics International Inc up on Friday (IPCI)June 10, 2023 | theglobeandmail.comIntellipharmaceutics International reports FY 2022 and Q1 2023 resultsJune 6, 2023 | msn.comSee More Headlines IPCIF Stock Analysis - Frequently Asked Questions How were Intellipharmaceutics International's earnings last quarter? Intellipharmaceutics International Inc. (OTCMKTS:IPCIF) issued its quarterly earnings results on Monday, July, 16th. The company reported ($0.70) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.70). The firm had revenue of $580 thousand for the quarter, compared to the consensus estimate of $900 thousand. When did Intellipharmaceutics International's stock split? Intellipharmaceutics International's stock reverse split on the morning of Friday, September 14th 2018.The 1-10 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of Intellipharmaceutics International own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intellipharmaceutics International investors own include Micron Technology (MU), Eyepoint Pharmaceuticals (EYPT), Aurinia Pharmaceuticals (AUPH), Anavex Life Sciences (AVXL), Protalix BioTherapeutics (PLX), Chesapeake Energy (CHKAQ) and BioLineRx (BLRX). Company Calendar Today11/14/2026Fiscal Year End11/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:IPCIF CIK1474835 Webwww.intellipharmaceutics.com Phone416-798-3001Fax416-798-3007Employees10Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$660 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($0.32) per share Price / BookN/AMiscellaneous Outstanding Shares33,093,000Free Float32,511,000Market Cap$4.96 million OptionableNot Optionable Beta1.53 The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:IPCIF) was last updated on 11/6/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredManagement just bought 2.8 million sharesManagement just backed a $100 million buyback, repurchasing 2.8 million shares at an average price of $35.26 i...Monument Traders Alliance | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intellipharmaceutics International Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intellipharmaceutics International With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IPCIF Stock Alerts